drugset / Trial / NCT02081001
PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients
Phase 2
Completed
19 enrolled
Xeris Pharmaceuticals
Emissary International LLC · collabNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedCrossoverDouble-blindTreatment
Summary
The purpose of the study is to assess the safety, speed of absorption, and onset of action of G-Pump™ (glucagon infusion) at three subcutaneous doses as compared to Novo GlucaGen®, all delivered via an OmniPod® infusion pump to patients with type 1 diabetes.
Timeline
- Start
- 2014-03
- Primary completion
- 2014-08
- Completion
- 2014-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | G-Pump | Unknown | 0.3 ug/kg | Subcutaneous |
| Subject | G-Pump | Unknown | 1.2 ug/kg | Subcutaneous |
| Subject | G-Pump | Unknown | 2 ug/kg | Subcutaneous |
| Subject | Glucagon | Peptide | 0.3 ug/kg | Subcutaneous |
| Subject | Glucagon | Peptide | 1.2 ug/kg | Subcutaneous |
| Subject | Glucagon | Peptide | 2 ug/kg | Subcutaneous |